Prize Winners Announced in $1.55M Challenge for New Solutions to Detect Opioids in International Mail

Newswise — WASHINGTON - Today, the U.S. Department of Homeland Security (DHS) Science and Technology Directorate (S&T), the White House Office of National Drug Control Policy (ONDCP), U.S. Customs and Border Protection (CBP), and the U.S. Postal Inspection Service (USPIS) announced the grand prize winner and runner-up in the Opioid Detection Challenge, a $1.55 million global prize competition for rapid, nonintrusive detection tools that will help find illicit opioids in international mail.  

IDSS will receive the grand prize of $500,000 for its detection solution, which combines a 3D X-ray computed tomography (CT) scanner with automated detection algorithms. The IDSS Detect 1000 identifies anomalies in X-ray images based on the scanned item’s features and physical properties.

The runner-up, One Resonance, will receive $250,000 for its detection solution, the QROD system, which is a quadrupole resonance technology that uses radio-frequency signals to search for specific materials. An alarm is triggered when a signal associated with an illicit substance is detected.

“The influx of illicit drugs is one of the nation’s greatest threats,” said William N. Bryan, DHS Senior Official Performing the Duties of Under Secretary for Science and Technology. “Through this combined effort to address the trafficking of opioids, S&T, our federal partners, and the private sector have produced technology solutions that will better protect the American people from the effects of this devastating crisis.”

Mr. Bryan was joined by CBP Deputy Commissioner Robert E. Perez, ONDCP Director Jim Carroll, and USPIS Chief Postal Inspector Gary Barksdale to announce the winners and recognize the finalists.  

“The Trump Administration is committed to reversing the effects of the drug crisis through both traditional practices and creative, unique methods,” said ONDCP Director Carroll. “This Challenge brought our whole-of-government approach together with the private sector to find ways to stop the flow of deadly substances into our country, which raise a grave national security concern. I congratulate the winners and thank them for sharing our commitment to accomplishing our ultimate goal of saving American lives.”

“In fiscal year 2019, our agents and officers seized nearly 2,600 pounds of fentanyl compared with 1,895 pounds in fiscal year 2018,” said CBP Deputy Commissioner Perez. “This is an alarming 35% increase over the course of one year and international mail has been one of the places that we are seeing illicit opioids come into the United States. Emerging technologies that can help us stop the flow of opioids across our borders are critical to the fight against the opioid epidemic.”

USPIS Chief Postal Inspector Barksdale added that, “opioids, such as fentanyl, have become a public health crisis, impacting our nation, states, towns, communities, homes and families. Through this Challenge, the Postal Service and other agencies are joining forces so that together we can develop new technologies that will help combat the opioid epidemic and thwart the distribution of illegal drugs or other harmful substances through the mail. The Postal Inspection Service is dedicated to ridding the mail of illicit drug trafficking, preserving the integrity of the mail, and most importantly, providing a safe environment for postal employees and the American public.”

Earlier this year, eight finalists received $100,000 each and advanced to the next stage of the Challenge. Since June, finalists continued to develop their plans into prototypes that underwent vigorous testing at the Transportation Security Laboratory. This culminated in a live test of their prototypes.

Winners were selected by a judging panel of experts in forensic science, postal operations, drug interdiction, and industrial engineering using specific selection criteria to identify technologies that will help intercept the flow of opioids through international mail.

S&T and its government partners plan to continue working with the providers of the most promising Challenge solutions to further develop prototypes and establish follow-on production agreements. The government plans to deploy these tools in international mail facilities, express consignment facilities, and other environments across the country that call for rapid, accurate detection of opioids and related substances.

For additional information about the Opioid Detection Prize Challenge and other S&T prize competitions, visit https://www.dhs.gov/science-and-technology/Challenge-Updates.




Filters close

Showing results

110 of 4573
Released: 15-Jan-2021 5:40 PM EST
Research Links Social Isolation to COVID-19 Protocol Resistance
Humboldt State University

As health officials continue to implore the public to wear masks and practice social distancing, recent research by Humboldt State University Psychology Professor Amber Gaffney provides key insights into connections between social isolation, conspiratorial thinking, and resistance to COVID-19 protocols.

Newswise: Rapid blood test identifies COVID-19 patients at high risk of severe disease
Released: 15-Jan-2021 5:35 PM EST
Rapid blood test identifies COVID-19 patients at high risk of severe disease
Washington University in St. Louis

Scientists at Washington University School of Medicine in St. Louis have shown that a relatively simple and rapid blood test can predict which patients with COVID-19 are at highest risk of severe complications or death. The blood test measures levels of mitochondrial DNA, which normally resides inside the energy factories of cells. Mitochondrial DNA spilling out of cells and into the bloodstream is a sign that a particular type of violent cell death is taking place in the body.

Released: 15-Jan-2021 2:55 PM EST
COVID-19 deaths really are different. But best practices for ICU care should still apply, studies suggest.
Michigan Medicine - University of Michigan

COVID-19 deaths are indeed different from other lung failure deaths, according to two recent studies, with 56% of COVID-19 patients dying primarily from the lung damage caused by the virus, compared with 22% of those whose lungs fail due to other causes. But, the researchers conclude, the kind of care needed to help sustain people through the worst cases of all forms of lung failure is highly similar, and just needs to be fine-tuned.

Released: 15-Jan-2021 2:50 PM EST
45% of adults over 65 lack online medical accounts that could help them sign up for COVID-19 vaccinations
Michigan Medicine - University of Michigan

As the vaccination of older adults against COVID-19 begins across the country, new poll data suggests that many of them don’t yet have access to the “patient portal” online systems that could make it much easier for them to schedule a vaccination appointment. In all, 45% of adults aged 65 to 80 had not set up an account with their health provider’s portal system.

Released: 15-Jan-2021 1:30 PM EST
New England Journal of Medicine publishes COVID-19 treatment trial results
University of Texas at San Antonio

A clinical trial involving COVID-19 patients hospitalized at UT Health San Antonio and University Health, among roughly 100 sites globally, found that a combination of the drugs baricitinib and remdesivir reduced time to recovery, according to results published Dec. 11 in the New England Journal of Medicine.

Released: 15-Jan-2021 12:40 PM EST
DNA test can quickly identify pneumonia in patients with severe COVID-19, aiding faster treatment
University of Cambridge

Researchers have developed a DNA test to quickly identify secondary infections in COVID-19 patients, who have double the risk of developing pneumonia while on ventilation than non-COVID-19 patients.

Released: 15-Jan-2021 12:30 PM EST
Fight CRC To Present Research Findings on The Impact of COVID-19 on the Colorectal Cancer Community at 2021 GI ASCO
Fight Colorectal Cancer

Fight Colorectal Cancer presents abstract at Gastrointestinal Cancer Symposium highlighting the need to address the barriers and opportunities for care within the colorectal cancer community during the COVID-19 pandemic

Released: 15-Jan-2021 12:25 PM EST
Technion to Award Honorary Doctorate to Pfizer CEO Dr. Albert Bourla
American Technion Society

Israel's Technion will award an honorary doctorate to Pfizer CEO and Chairman Dr. Albert Bourla, for leading the development of the novel vaccine against SARS-CoV-2, the virus that causes COVID-19. The honorary doctorate will be conferred at the Technion Board of Governors meeting in November 2021.

Released: 15-Jan-2021 11:30 AM EST
UW researchers develop tool to equitably distribute limited vaccines
University of Wisconsin-Madison

Researchers at the University of Wisconsin School of Medicine and Public Health and UW Health have developed a tool that incorporates a person’s age and socioeconomic status to prioritize vaccine distribution among people who otherwise share similar risks due to their jobs.


Showing results

110 of 4573

close
0.8379